Deutetrabenazine modestly reduces chorea of Huntington disease

A deuterated form of the vesicular monoamine transporter type 2 inhibitor tetrabenazine, called deutetrabenazine, modestly reduced chorea of Huntington disease over 12 weeks in a phase III,...
Source: Clinical Neurology News - Category: Neurology Source Type: news